Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast cancer. It is yet unclear whether addition of capecitabine to the combination of these drugs improves the treatment outcome. Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin®) and paclitaxel (Taxol®) alone (ET) or in combination with capecitabine (Xeloda®, TEX). Starting doses for ET were epirubicin 75 mg/m2 plus paclitaxel 175 mg/m2, and for TEX epirubicin 75 mg/m2, paclitaxel 155 mg/m2, and capecitabine 825 mg/m2 BID for 14 days. Subsequently, doses were tailored related to side effects. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), time to treatment failure (TTF), objective response (OR), safety and quality of life (QoL). 287 patients were randomized, 143 to ET and 144 to TEX. Median PFS was 10.8 months for patients treated with ET, and 12.4 months for those treated with TEX (HR 0.84, 95% CI 0.65–1.07, P = 0.16); median OS was 26.0 months for women in the ET versus 29.7 months in the TEX arm (HR 0.84, 95% CI 0.63–1.11, P = 0.22). OR was achieved in 44.8% (ET) and 54.2% (TEX), respectively (χ2 3.66, P = 0.16). TTF was significantly longer for patients treated with TEX, 6.0 months, versus 5.2 months following ET (HR 0.73, 95% CI 0.58–0.93, P = 0.009). Severe hematological side effects related to epirubicin and paclitaxel were evenly distributed between the treatment arms, mucositis, diarrhea, and Hand-Foot syndrome were significantly more frequent in the TEX arm. Toxicity-adjusted treatment with ET and TEX showed similar efficacy in terms of PFS, OS, and OR. In this trial with limited power, the addition of capecitabine to epirubicin and paclitaxel as first-line treatment did not translate into clinically relevant improvement of the outcome.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Sledge GW, Neuberg D, Bernardo P, Ingle JN et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 21:588–592
Miwa M, Ura M, Nishida M, Sawada N et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281
Ishitsuka H (2000) Capecitabine: preclinical pharmacology studies. Invest New Drugs 18:343–354
Sawada N, Ishikawa T, Fukase Y, Nishida M et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019
Puglisi F, Cardellino GG, Crivellari D, Di Loreto C et al (2008) Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 19:1541–1546
Toi M, Bando H, Horiguchi S, Takada M et al (2004) Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 90:2338–2343
Batista N, Perez-Manga G, Constenla M, Ruiz A et al (2004) Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 90:1740–1746
Venturini M, Durando A, Garrone O, Colozza MA et al (2003) Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 97:1174–1180
Mansutti M, Cavazzini G, Lorusso V, Boni C et al (2008) Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC). J Clin Oncol 26:49s (May 20 suppl; abstr 1034)
Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281–1288
Baker SD, Verweij J, Rowinsky EK, Donehower RC et al (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. JNCI 94:1883–1888
Gurney HP, Ackland S, Gebski V, Farell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299–2304
Wiechec E, Hansen LL (2009) The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol 625:122–130
Einbeigi Z, Bergström D, Hatschek T, Malmberg M (2008) Paclitaxel, epirubicin and capecitabine (TEX) as first-line treatment for metastatic breast cancer: a pilot phase I/II feasibility study. Clin Med Oncol 2:533–538
Jassem J, Pienkowski T, Pluzanska A, Jelic S et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2—positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23:4265–4274
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
WHO (1979) WHO Handbook for reporting results of cancer treatment. World Health Organization. WHO Offset Publication No. 48, Geneva
Collett D (1994) Modelling survival data in medical research. Chapman & Hall, London, p 255
Butters DJ, Ghersi D, Wilcken N, Kirk SJ et al (2010) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer (Review). The Cochrane Collaboration. Wiley, Chichester
Ghersi D, Wilcken N, Simes J, Donoghue E (2008) Taxane containing regimens for metastatic breast cancer (Review). The Cochrane Collaboration. Wiley, Chichester
Biganzoli L, Cufer T, Bruning P (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114–3121
Venturini M, Paridaens R, Rossner D, Vaslamatzis MM et al (2007) An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology 72:51–57
Fossati R, Confalonierir C, Torri V, Ghislandi E et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31, 510 women. J Clin Oncol 16:3439–3460
Jones SE, Erban J, Overmoyer B, Budd GT et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–5551
Wilking N, Lidbrink E, Wiklund T, Erikstein B et al (2007) Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18:694–700
Gamelin E, Delva R, Jacob J, Merrouche Y et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–2105
Fleming RA, Milano G, Thyss A, Etienne MC et al (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899–2902
Honda J, Sasa M, Moriya T, Bando Y et al (2008) Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer—preliminary results. J Med Invest 55:54–60
Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y (2010) Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat 123:785–793
Members of the Independent Review Committee Prof. Lars Holmberg, Division of Cancer Studies, King’s College, London, UK, Assoc. Prof. Torgil Möller, Dept of Cancer Epidemiology, Lund University, Sweden, and Prof. Erik Wist, Oslo University Hospital, Oslo, Norway, for constructive discussions during the study.
Unrestricted grants from Bristol-Myers Squibb Sweden AB, Pfizer Sweden AB and Roche Sweden AB, the Research Funds at Radiumhemmet, the Swedish Cancer Society, the Swedish Breast Cancer Association (BRO) and ALF/FOU research funds at the Karolinska Institutet and Stockholm County Council.
Conflict of interest
T. Hatschek: Consulting/advisory role: Pfizer; Funding: Roche, Sanofi-aventis. L. Carlsson: None. Z. Einbeigi: None. E. Lidbrink: None. B. Linderholm: None. B. Lindh: None. N. Loman: None. M. Malmberg: None. S. Rotstein: None. M. Söderberg: Consultant/advisory role: BMS, Roche. M. Sundquist: None. T. M. Walz: None. M. Hellström: None. K. Hammarlund: None. H. Svensson: None. G. Åström: None. Y. Brandberg: None. J. Carstensen: None. M. Fernö: None. J. Bergh: Consultant/advisory role: Amgen, Astrazeneca, GlaxoSmithKline, Pfizer, Sanofi-aventis; Funding: Amgen, Merck, Sanofi-aventis.
This study was conducted on behalf of TEX study group.
Participating investigators of the TEX study group are given in Appendix.
Participating investigators of the TEX study group
Coordinating Investigator: Thomas Hatschek, Translational research: Mårten Fernö, QoL: Yvonne Brandberg, Statistics: John Carstensen, Laboratory: Suzanne Egyhazy, Marianne Frostvik Stolt, Lambert Skogh, Clinical Trial Office: Mats Hellström, Maarit Maliniemi, Helene Svensson, Radiology: Gunnar Åström, Departments of Oncology at 1. Karolinska University Hospital, Stockholm: Jonas Bergh, Judith Bjöhle, Elisabet Lidbrink, Sam Rotstein, Birgitta Wallberg, 2. Sahlgrenska University Hospital, Gothenburg: Zakaria Einbeigi, Per Carlsson, Barbro Linderholm, 3. Linköping University Hospital: Thomas M Walz, 4. Skåne University Hospital Malmö: Martin Söderberg, 5. Skåne University Hospital Lund: Niklas Loman, Per Malmström, 6. Helsingborg General Hospital: Martin Malmberg, 7. Sundsvall General Hospital: Lena Carlsson, 8. Umeå University Hospital: Birgitta Lindh, 9. Kalmar General Hospital: Marie Sundqvist, 10. Karlstad General Hospital: Lena Malmberg.
About this article
Cite this article
Hatschek, T., Carlsson, L., Einbeigi, Z. et al. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat 131, 939–947 (2012). https://doi.org/10.1007/s10549-011-1880-9
- Advanced breast cancer
- First-line treatment